CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies.
We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability.
CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.
Location: United Kingdom, England, Bristol
Employees: 1-10
Total raised: $6.48M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | SCVC | scvc.com |
| - | Outsized V... | outsized.v... |
| - | Parkwalk A... | parkwalkad... |
| 18.03.2021 | Luminous V... | luminous.v... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| - | - | $1.53M | - |
| - | - | $4.95M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 16.03.2021 | Bristol biotech bags £3.5M to develop next-gen cell therapy ... | Healthcare has progressed rapidly in recent years, thanks to the latest technological innovations. N... | uktech.new... |
| - | Bristol biotech bags £3.5M to develop next-gen cell therapy ... | Healthcare has progressed rapidly in recent years, thanks to the latest technological innovations. N... | uktech.new... |
| - | CytoSeek – raises £3.57m funding round | CytoSeek raises £3.57m to advance its mission to develop the next generation of cell therapies for c... | parkwalkad... |
| - | Cytoseek – raises £1.1m for new cell therapies | We are delighted that the University of Bristol Enterprise Fund managed by Parkwalk, has invested in... | parkwalkad... |